This biotech company develops pharmaceutical therapies that target the excitatory-inhibitory balance in the brain to improve cognitive function. Their drugs aim to treat cognitive impairments associated with conditions like Alzheimer's and schizophrenia by modulating neural activity related to learning and memory.
Funding
Funding not disclosed
Founders
Product
Problem
Cognitive impairments are a common symptom across various central nervous system diseases and disorders, significantly impacting patients' quality of life and placing a burden on caregivers and healthcare systems. Current treatments often fall short of addressing these cognitive deficits, leaving a substantial unmet need in mental healthcare.
Solution
Recognify Life Sciences is developing pharmaceutical therapies to address cognitive impairment, particularly Cognitive Impairment Associated with Schizophrenia (CIAS). Their lead asset, RL-007, is an orally available small molecule designed to modulate the excitatory/inhibitory balance in the brain, thereby improving learning and memory. RL-007 has demonstrated pro-cognitive and anxiolytic effects in preclinical studies, enhancing long-term potentiation in rat hippocampal slices. Clinical trials have shown improvements in verbal learning and memory in human subjects.
Target Audience
The primary target audience includes individuals suffering from cognitive impairments associated with neurological and psychiatric disorders, such as Cognitive Impairment Associated with Schizophrenia (CIAS).
Features
- RL-007: A proprietary GABA/nicotinic modulator designed to improve cognitive function.
- Orally available small molecule for convenient administration.
- Demonstrated pro-cognitive effects in preclinical models of healthy aging and cholinergic deficits.
- Anxiolytic properties observed in animal models of unconditioned anxiety.
- Enhancement of long-term potentiation in rat hippocampal slices, indicating a direct impact on learning and memory mechanisms.
- Evaluated in nine clinical studies, including Phase I and Phase II trials, with over 500 subjects dosed.
- Clinical trials have demonstrated improvements in verbal learning and memory.